{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:32:00Z","timestamp":1782912720360,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. U24A20758, 82071967, 82202218"],"award-info":[{"award-number":["No. U24A20758, 82071967, 82202218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["No. L242062"],"award-info":[{"award-number":["No. L242062"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["No. 2024YFC2419400, 2024YFC2419401"],"award-info":[{"award-number":["No. 2024YFC2419400, 2024YFC2419401"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["No. CIFMS-2023-I2M-2-002, CIFMS-2021-I2M-1-002, CIFMS-2021-I2M-1-003, CIFMS-2021-I2M-1-025, 2024-12M-ZD-001"],"award-info":[{"award-number":["No. CIFMS-2023-I2M-2-002, CIFMS-2021-I2M-1-002, CIFMS-2021-I2M-1-003, CIFMS-2021-I2M-1-025, 2024-12M-ZD-001"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["No. 2022-PUMCH-D-001, 2022-PUMCH-D-002, 2022-PUMCH-B-072"],"award-info":[{"award-number":["No. 2022-PUMCH-D-001, 2022-PUMCH-D-002, 2022-PUMCH-B-072"]}]},{"name":"Peking Union Medical College Hospital Talent Cultivation Program Category D","award":["UHB12582"],"award-info":[{"award-number":["UHB12582"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00259-025-07484-9","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T05:24:07Z","timestamp":1754371447000},"page":"954-967","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessment of the diagnostic efficacy and clinical significance of [18F]AlF-NOTA-LM3 PET\/CT in patients with well-differentiated neuroendocrine tumors"],"prefix":"10.1007","volume":"53","author":[{"given":"Meixi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-083X","authenticated-orcid":false,"given":"Li","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"issue":"5","key":"7484_CR1","first-page":"426","volume":"4","author":"A Mojtahedi","year":"2014","unstructured":"Mojtahedi A, Thamake S, Tworowska I, Ranganathan D, Delpassand ES. The value of (68)Ga-DOTATATE PET\/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. Am J Nucl Med Mol Imaging. 2014;4(5):426\u201334.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"7","key":"7484_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844\u201360.","journal-title":"Ann Oncol"},{"issue":"9","key":"7484_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13423","volume":"36","author":"A Lamarca","year":"2024","unstructured":"Lamarca A, Bartsch DK, Caplin M, et al. European neuroendocrine tumor society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours. J Neuroendocrinol. 2024;36(9): e13423.","journal-title":"J Neuroendocrinol"},{"issue":"12","key":"7484_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13343","volume":"35","author":"B Kos-Kud\u0142a","year":"2023","unstructured":"Kos-Kud\u0142a B, Casta\u00f1o JP, Denecke T, et al. European neuroendocrine tumour society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol. 2023;35(12): e13343.","journal-title":"J Neuroendocrinol"},{"issue":"2","key":"7484_CR5","doi-asserted-by":"publisher","first-page":"e220290","DOI":"10.1001\/jamanetworkopen.2022.0290","volume":"5","author":"S Pusceddu","year":"2022","unstructured":"Pusceddu S, Prinzi N, Tafuto S, Ibrahim T, Filice A, Brizzi MP, et al. Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors. JAMA Netw Open. 2022;5(2):e220290.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"7484_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"12","key":"7484_CR7","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. (177)Lu-dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752\u201363.","journal-title":"Lancet Oncol"},{"issue":"9","key":"7484_CR8","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.122.264890","volume":"64","author":"Z Lin","year":"2023","unstructured":"Lin Z, Zhu W, Zhang J, Miao W, Yao S, Huo L. Head-to-head comparison of (68)Ga-NODAGA-JR11 and (68)Ga-DOTATATE PET\/CT in patients with metastatic, well-differentiated neuroendocrine tumors: interim analysis of a prospective bicenter study. J Nucl Med. 2023;64(9):1406\u201311.","journal-title":"J Nucl Med"},{"issue":"6","key":"7484_CR9","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2967\/jnumed.117.199760","volume":"59","author":"GP Nicolas","year":"2018","unstructured":"Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, et al. Sensitivity comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J Nucl Med. 2018;59(6):915\u201321.","journal-title":"J Nucl Med"},{"issue":"6","key":"7484_CR10","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2967\/jnumed.119.235093","volume":"61","author":"W Zhu","year":"2020","unstructured":"Zhu W, Cheng Y, Wang X, Yao S, Bai C, Zhao H, et al. Head-to-head comparison of (68)Ga-DOTA-JR11 and (68)Ga-DOTATATE PET\/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study. J Nucl Med. 2020;61(6):897\u2013903.","journal-title":"J Nucl Med"},{"issue":"5","key":"7484_CR11","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s00259-021-05512-y","volume":"49","author":"W Zhu","year":"2022","unstructured":"Zhu W, Jia R, Yang Q, Cheng Y, Zhao H, Bai C, et al. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of (68)Ga-NODAGA-LM3 and (68)Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with (68)Ga-DOTATATE. Eur J Nucl Med Mol Imaging. 2022;49(5):1613\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7484_CR12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2967\/jnumed.123.265622","volume":"64","author":"H Leupe","year":"2023","unstructured":"Leupe H, Ahenkorah S, Dekervel J, Unterrainer M, Van Cutsem E, Verslype C, et al. (18)F-labeled somatostatin analogs as PET tracers for the somatostatin receptor: ready for clinical use. J Nucl Med. 2023;64(6):835\u201341.","journal-title":"J Nucl Med"},{"issue":"16","key":"7484_CR13","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.7150\/thno.99025","volume":"14","author":"K Cheng","year":"2024","unstructured":"Cheng K, Wang S, Liu T, Pei J, Wang S, Liu J, et al. PET imaging of CXCR4 expression using [(18)F]AlF-NOTA-QHY-04 for hematologic malignancy and solid tumors. Theranostics. 2024;14(16):6337\u201349.","journal-title":"Theranostics"},{"issue":"2","key":"7484_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2967\/jnumed.120.245084","volume":"62","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, Adeberg S, Syed M, Lindner T, Jim\u00e9nez-Franco LD, Mavriopoulou E, et al. FAPI-74 PET\/CT using either (18)F-AlF or cold-kit (68)Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med. 2021;62(2):201\u20137.","journal-title":"J Nucl Med"},{"issue":"4","key":"7484_CR15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.119.234187","volume":"61","author":"J Kuten","year":"2020","unstructured":"Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-head comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. 2020;61(4):527\u201332.","journal-title":"J Nucl Med"},{"issue":"6","key":"7484_CR16","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00259-023-06587-5","volume":"51","author":"N Liu","year":"2024","unstructured":"Liu N, Wan Q, Wu X, Zhao T, Jakobsson V, Yuan H, et al. A comparison of [(18)F]AlF- and (68)Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET\/CT imaging. Eur J Nucl Med Mol Imaging. 2024;51(6):1685\u201397.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7484_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2967\/jnumed.122.264563","volume":"64","author":"E Pauwels","year":"2023","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, et al. (18)F-AlF-NOTA-octreotide outperforms (68)Ga-DOTATATE\/NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study. J Nucl Med. 2023;64(4):632\u20138.","journal-title":"J Nucl Med"},{"issue":"12","key":"7484_CR18","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1007\/s00259-024-06790-y","volume":"51","author":"M Liu","year":"2024","unstructured":"Liu M, Ren C, Zhang H, Zhang Y, Huang Z, Jia R, et al. Evaluation of the safety, biodistribution, dosimetry of [(18)F]AlF-NOTA-LM3 and head-to-head comparison with [(68)Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial. Eur J Nucl Med Mol Imaging. 2024;51(12):3719\u201330.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7484_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0026-895X(25)09370-8","volume":"50","author":"RT Bass","year":"1996","unstructured":"Bass RT, Buckwalter BL, Patel BP, Pausch MH, Price LA, Strnad J, et al. Identification and characterization of novel somatostatin antagonists. Mol Pharmacol. 1996;50(4):709\u201315.","journal-title":"Mol Pharmacol"},{"issue":"7","key":"7484_CR20","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1007\/s00259-024-06639-4","volume":"51","author":"M Liu","year":"2024","unstructured":"Liu M, Cheng Y, Bai C, Zhao H, Jia R, Chen J, et al. Gallium-68 labeled somatostatin receptor antagonist PET\/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China. Eur J Nucl Med Mol Imaging. 2024;51(7):2002\u201311.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 2","key":"7484_CR21","doi-asserted-by":"publisher","first-page":"s61","DOI":"10.2967\/jnumed.116.186783","volume":"58","author":"M Fani","year":"2017","unstructured":"Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy. J Nucl Med. 2017;58(Suppl 2):s61-6.","journal-title":"J Nucl Med"},{"issue":"15","key":"7484_CR22","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1021\/acs.jcim.3c00712","volume":"63","author":"S Gervasoni","year":"2023","unstructured":"Gervasoni S, \u00d6zt\u00fcrk I, Guccione C, Bosin A, Ruggerone P, Malloci G. Interaction of radiopharmaceuticals with somatostatin receptor 2 revealed by molecular dynamics simulations. J Chem Inf Model. 2023;63(15):4924\u201333.","journal-title":"J Chem Inf Model"},{"issue":"9","key":"7484_CR23","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2967\/jnumed.112.102764","volume":"53","author":"M Fani","year":"2012","unstructured":"Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012;53(9):1481\u20139.","journal-title":"J Nucl Med"},{"issue":"10","key":"7484_CR24","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00259-021-05249-8","volume":"48","author":"Q Xie","year":"2021","unstructured":"Xie Q, Liu T, Ding J, Zhou N, Meng X, Zhu H, et al. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [(18)F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [(68)Ga]Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2021;48(10):3129\u201340.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7484_CR25","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1097\/RLU.0000000000002906","volume":"45","author":"J Zhang","year":"2020","unstructured":"Zhang J, Kulkarni HR, Singh A, Baum RP. Successful Intra-arterial peptide receptor radionuclide therapy of DOTATOC-Negative High-Grade liver metastases of a pancreatic neuroendocrine neoplasm using 177Lu-DOTA-LM3: A somatostatin receptor antagonist. Clin Nucl Med. 2020;45(3):e165\u20138.","journal-title":"Clin Nucl Med"},{"issue":"11","key":"7484_CR26","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2967\/jnumed.120.258889","volume":"62","author":"RP Baum","year":"2021","unstructured":"Baum RP, Zhang J, Schuchardt C, M\u00fcller D, M\u00e4cke H. First-in-humans study of the SSTR antagonist (177)Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety, and efficacy. J Nucl Med. 2021;62(11):1571\u201381.","journal-title":"J Nucl Med"},{"issue":"3","key":"7484_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000381061","volume":"101","author":"G Kanakis","year":"2015","unstructured":"Kanakis G, Grimelius L, Spathis A, Tringidou R, Rassidakis GZ, \u00d6berg K, et al. Expression of somatostatin receptors 1\u20135 and dopamine receptor 2 in lung carcinoids: implications for a therapeutic role. Neuroendocrinology. 2015;101(3):211\u201322.","journal-title":"Neuroendocrinology"},{"issue":"12","key":"7484_CR28","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1007\/s00259-022-05848-z","volume":"49","author":"V Rufini","year":"2022","unstructured":"Rufini V, Lorusso M, Inzani F, Pasciuto T, Triumbari EKA, Grillo LR, et al. Correlation of somatostatin receptor PET\/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study. Eur J Nucl Med Mol Imaging. 2022;49(12):4182\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7484_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000508633","volume":"111","author":"M Cives","year":"2021","unstructured":"Cives M, Pell\u00e8 E, Rinzivillo M, Prosperi D, Tucci M, Silvestris F, et al. Bone metastases in neuroendocrine tumors: molecular pathogenesis and implications in clinical practice. Neuroendocrinology. 2021;111(3):207\u201316.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"7484_CR30","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1007\/s00330-020-07554-6","volume":"31","author":"N Deleval","year":"2021","unstructured":"Deleval N, Pesque L, Dieudonn\u00e9 A, Viry F, Hentic O, Lebtahi R, et al. Prognostic impact of bone metastases detected by (18)F-DOPA PET in patients with metastatic midgut neuroendocrine tumors. Eur Radiol. 2021;31(6):4166\u201374.","journal-title":"Eur Radiol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07484-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07484-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07484-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:46:07Z","timestamp":1769222767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07484-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7484"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07484-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article was modified to correct the funding statement.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were carried out in accordance with with the principles of the Helsinki Declaration. The study was approved by the institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors affirm that human research participants provided informed consent for the publication of the images in all figures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no conflicts of interest to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}